GSK plans to acquire a multiple myeloma drug candidate from China-based Chimagen Biosciences for up to $750 million, the companies announced Tuesday.
Why it matters: China-origin biotech deals are continuing a record run, raising questions over how the U.S. should respond to the country's rapid gains.
